How about using Chinese speaking volunteers to broker mask deals?
My sense is that the market between suppliers in China and hospitals in need in many countries isn't very efficient, but I could be wrong.
I have a call tomorrow with someone who knows more about wholesale buying in China.
Mitigation work seems very low on neglectedness.
I'd encourage more work on planning for post-COVID reactions and policy proposals, as well as thinking about how EAs can be in a good position to influence such decisions.
Could you be more specific or provide an example?
People should be working on funding proposals for Bio-X risk mitigation policies, such as greater international coordination, better health monitoring systems, investment in non-disease specific symptomatic surveillance, and similar. These are likely to be far easier to fund in 3-6 months, as a huge pool of money is allocated to work on fixing the next pandemic.